Download PDF
Thromb Haemost 1994; 72(05): 784-785
DOI: 10.1055/s-0038-1648960
Letter to the Editor
Schattauer GmbH Stuttgart

Variables that Might Affect the Outcome of Immune Tolerance Therapy in Haemophiliacs with Factor VIII Inhibitors

S Ehrenforth
1   Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany
,
W Kreuz
1   Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany
,
M Funk
1   Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany
,
G Auerswald
2   Department of Paediatrics, Prof.-Hess-Hospital, Bremen, Germany
,
I Scharrer
1   Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

Received 08 June 1994

Accepted after revision 28 July 1994

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Schwarzinger I, Pabinger I, Kominger C, Haschke F, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor FVIII concentrates. Am J Hematol 1987; 24: 241-245
    CrossrefPubMedGoogle Scholar
  • 1 Schwarz RS, Abildgaard CF, Aledort LM, Arkin S, Blom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ. Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1799-1805
    PubMedGoogle Scholar
  • 3 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371
    CrossrefPubMedGoogle Scholar
  • 4 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
    CrossrefPubMedGoogle Scholar
  • 5 Brackmann HH. Induced immunotolérance in factor VIII inhibitor patients. Prog Clin Biol Res 1986; 150: 181-185
    PubMedGoogle Scholar
  • 6 Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. and the Danish Study Group Continous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost 1987; 58: 1049
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kasper CK. Treatment of factor VIII inhibitors. Progr Hemostas Thromb 1989; 9: 57-86
    PubMedGoogle Scholar
  • 8 Lusher JM. Factor VIII inhibitors. Etiology, characterisation, natural history and management. In: Factor VIII/vWF, platelet formation and function in health and disease. A tribute to Marion Barnhart I, Lusher JM, Mammen EF, McCoy L, Walz D. eds Ann NY Acad Sci; 1987. 509 089-102
  • 9 Ewing NP. Induction of Immune Tolerance with Factor VIII Concentrate in Patients with Hemophilia A and Inhibitors. In: Recent Advances in Hemophilia Care Kasper CK. ed Alan R Liss Inc; NY: 1990. pp 59-68
  • 10 Hedner U, Glazer S. Management of hemophilia patients with inhibitors. In: Coagulation disorders I 1992. 5 1035-1046
  • 11 Mariani G, Ghirardini A, Bellocco R. Immune Tolerance in Hemophilia -Principal Results from the International Registry. Thromb Haemost 1994; 72: 155-158
    Article in Thieme ConnectPubMedGoogle Scholar